Fig. 6: mAbs and Nbs binding to RBD are differently affected by mutations in the circulating variants. | Nature Communications

Fig. 6: mAbs and Nbs binding to RBD are differently affected by mutations in the circulating variants.

From: Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes

Fig. 6: mAbs and Nbs binding to RBD are differently affected by mutations in the circulating variants.

a Localization of six RBD residues where major circulating variants mutate. b Buried surface area of Nbs by different RBD residues. c Buried surface area of Fabs by different RBD residues. d, e Representative structures of different classes of Nbs with major variant residues shown as spheres. Two Fab structures that bind similarly to Class I Nbs were shown on the side. f The boxplot showing the probability of epitope residues coinciding with the variant mutations (n = 24, 15, and 56 for Nbs, in vivo matured Nbs, and Fabs, respectively). Box plots indicate median (middle line), 25th, 75th percentile (box), and 5th and 95th percentile (whiskers) as well as outliers (single points). Statistical analysis was performed using a two-tailed student t test, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

Back to article page